
Articles
-
Nov 5, 2024 |
nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more
AbstractMeasurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant.
-
Oct 24, 2024 |
nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more
AbstractRoutine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined.
-
Oct 17, 2024 |
nature.com | Niveditha Ravindra |Zoë C Wong |Jeffery J. Auletta |Steven M. Devine |Mark Litzow |Partow Kebriaei | +2 more
To the Editor:High relapse rates for patients despite potentially curative allogeneic hematopoietic cell transplant (alloHCT) remain a critical issue in acute myeloid leukemia (AML). Next-generation sequencing (NGS) represents a promising modality for measurable residual disease (MRD) testing in patients with AML, but the appropriate targets for monitoring must be defined [1,2,3,4,5,6,7].
-
Sep 16, 2024 |
medrxiv.org | Jason Dehn |Brent R. Logan |Bronwen E. Shaw |Steven M. Devine
S.J.L- Board of Directors, nmdp (uncompensated)A.S.-Consulting Fees: Sanofi and TherakosNCT03904134Support for this study was provided by grants #U10HL069294 and #U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute.
-
May 29, 2024 |
mdpi.com | Steven M. Devine |S. M
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →